Anzeige
Mehr »
Dienstag, 03.03.2026 - Börsentäglich über 12.000 News
1.000.000 $ staatliche Förderung - Startet hier Kanadas nächster Lithium-Champion?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40C39 | ISIN: US5049221055 | Ticker-Symbol: N6B
Tradegate
03.03.26 | 07:50
240,00 Euro
-2,44 % -6,00
Branche
Sonstige Technologie
Aktienmarkt
S&P 500
1-Jahres-Chart
LABCORP HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
LABCORP HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
242,00244,0021:18
244,00246,0021:01

Aktuelle News zur LABCORP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrDividendenbekanntmachungen (27.02.2026)17.495 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ACNB CORPORATION  US0008681092  0,38 USD  0,322 EUR  AGNC INVESTMENT CORP  US00123Q1040  0,12 USD  0,1017 EUR  AGREE REALTY CORPORATION  US0084921008  0...
► Artikel lesen
24.02.LABCORP HOLDINGS INC. - 10-K, Annual Report3
23.02.Labcorp Expands Collaboration With PathAI To Deploy AISight Dx Digital Pathology Platform292WASHINGTON (dpa-AFX) - Labcorp Holdings, Inc. (LH), a comprehensive laboratory services provider, announced Monday an expanded collaboration with PathAI to deploy AISight Dx, an FDA-cleared...
► Artikel lesen
LABCORP Aktie jetzt für 0€ handeln
23.02.Labcorp expands PathAI partnership to deploy digital pathology platform nationwide4
23.02.Labcorp expands PathAI collaboration for digital pathology rollout6
23.02.Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide140AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration...
► Artikel lesen
17.02.Labcorp outlines 5.4% midpoint revenue growth and 9% EPS target for 2026 while advancing specialty and AI initiatives2
17.02.Labcorp slips after Q4 revenue miss2
17.02.Labcorp Q4 Earnings Beat, Revenues Miss, Stock Down in Pre-Market2
17.02.Labcorp forecasts upbeat annual profit on strong demand for diagnostic products4
17.02.ROUNDUP: Labcorp Guides FY26 Adj. EPS Above Estimates244WASHINGTON (dpa-AFX) - While reporting financial results for the fourth quarter on Tuesday, life sciences company Labcorp Holdings, Inc.(LH) initiated its adjusted earnings and revenue guidance...
► Artikel lesen
17.02.Labcorp Holdings Inc. Announces Climb In Q4 Income266WASHINGTON (dpa-AFX) - Labcorp Holdings Inc. (LH) reported a profit for its fourth quarter that Increases, from last yearThe company's bottom line came in at $164.7 million, or $1.98 per share....
► Artikel lesen
17.02.Labcorp Holdings reports mixed results; initiates FY26 outlook4
17.02.LABCORP HOLDINGS INC. - 8-K, Current Report3
17.02.Labcorp Holdings Inc: Labcorp Announces 2025 Fourth Quarter and Full Year Results220Company Provides 2026 Guidance Financial results from Operations versus 2024: Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs...
► Artikel lesen
16.02.Earnings Outlook For Laboratory Corp2
13.02.Labcorp Holdings Q4 2025 Earnings Preview4
11.02.Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care312Elecsys® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathology Now available nationwide in primary...
► Artikel lesen
10.02.Labcorp's Q4 Earnings Preview: What's in Store for the Stock?5
09.02.Labcorp appoints neurosurgeon John Sampson to board of directors3
Weiter >>
103 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1